Fig. 5

Response rates at weeks 9–12 in the overall migraine population (all patients, n = 82), patients naïve to anti-CGRP mAbs (n = 48) and individuals with prior anti-CGRP mAb failures (n = 34). ≥ 50% responders: proportion of patients with a ≥ 50% reduction in monthly migraine/headache days compared to baseline; ≥ 75% responders: proportion of patients with a ≥ 75% reduction in monthly migraine/headache days compared to baseline; 100% responders: proportion of patients with a 100% reduction in monthly migraine/headache days compared to baseline